BRCA1 and triple-negative breast carcinoma: Since we initiated this study, the treatment landscape for patients with metastatic triple-negative breast cancer has evolved considerably, and two targeted approaches were recently approved: the anti-PD-L1 inhibitor atezolizumab in combination with nab-paclitaxel in PD-L1-positive triple-negative breast cancer [35], and the PARP inhibitors olaparib or talazoparib for germline BRCA1/BRCA2 mutation carriers [36, 37].